Clinical Trial Update: A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating gefapixant (MK-7264) for refractory or unexplained chronic cough in Japanese adults has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Cough | Phase 3 | Status: COMPLETED | Results posted: 2021-11-01